Faculty dinner

Welcome and introduction
Saad Usmani & Sham Mailankody

Session 1: Basic/pre-clinical
Chairs: TBC & TBC 

• GPRC5D: Pioneering a novel target for immunotherapy – From discovery to translation: Eric Smith
• Bispecific and trispecific antibodies targeting GPRC5D: Bradley Heidrich
• Spatially resolved expression of immunotherapy targets including GPRC5D: Neils Weinhold

Panel discussion

Session 2: Translational
Chairs: Ross Firestone & Eric Smith

• Talk title TBC (role of the microbiome): TBC
• Clonal evolution and impact on antigen expression: Holly Lee
• Quantitative analysis of myeloma antigen expression: Karlo Perica
• Predictors of response and resistance to talquetamab: Tarek Mouhieddine
• Genomic determinants of resistance to GPRC5D therapies: Francesco Maura

Panel discussion

Break

 

Session 3: Clinical updates
Chairs: Eric Jurgens & Hira Mian

• GPRC5D directed CAR T-cells in relapsed refractory multiple myeloma: Clinical update: Susan Bal
• GPRC5D bispecific antibodies: TBC
• GPRC5D antibody drug conjugates: Sridevi Rajeeve
• Bispecific antibody delivery in older/frailer patients: Charlotte Pawlyn

Panel discussion

 

Lunch

Session 4: Practical aspects of GPRC5D therapies (part I)
Chairs: TBC & Noopur Raje

• Infection risk with BCMA and GPRC5D therapies: Tomáš Jelínek
• Oral and GI toxicities associated with GPRC5D therapies: Andrew Yee
• Skin toxicities associated with GPRC5D therapies: Time to make rash decisions: Rahul Banerjee
• Management of GPRC5D-related toxicities: Joshua Richter

Panel discussion

Session 5: Practical aspects of GPRC5D therapies (part II)
Chairs: Charlotte Pawlyn & Andrew Yee

• Optimal sequencing of BCMA and GPRC5D therapies: Binod Dhakal
• Real-world outcomes with talquetamab: Hamza Hashmi
• RWE with talquetamab – European perspective: Marc Raab

Panel discussion

Meeting conclusions & close
Saad Usmani & Sham Mailankody